Cellectra 2000

DEVICE2 trials

Sponsors

Parker Institute for Cancer Immunotherapy, Abramson Cancer Center at Penn Medicine

Conditions

BRCA1/2 MutationMetastatic Castration-resistant Prostate Cancer

Phase 1

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

CompletedNCT03835533

Parker Institute for Cancer ImmunotherapyMetastatic Castration-resistant Prostate Cancer

Start: 2019-06-21End: 2022-10-03Updated: 2024-04-12

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Active, not recruitingNCT04367675

Abramson Cancer Center at Penn MedicineBRCA1/2 Mutation

Start: 2021-04-20End: 2027-03-01Target: 44Updated: 2026-02-23

Related Papers

Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with <i>BRCA1/2</i> mutations.

Journal of Clinical Oncology2025-05-281 citations

Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

Clinical Cancer Research2025-02-188 citations

559 Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 PORTER platform trial in metastatic castration-resistant prostate cancer patients

Regular and Young Investigator Award Abstracts2022-11-01

555 Clinical and pharmacodynamic biomarker results from PORTER, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients

Regular and Young Investigator Award Abstracts2022-11-01